Chemical feature-based pharmacophores and virtual library screening for discovery of new leads

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 3, 2003, Pages 370-376

  Langer, Thierry ^a,b   Krovat, Eva Maria ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Software Engineering and Consulting   (Austria)

Author keywords

Chemical feature based pharmacophore; High throughput screening; In silico screening; Pharmacophore modeling; Virtual combinatorial chemistry; Virtual compound library; Virtual screening

Indexed keywords

1 [4 (1H PYRROL 3 YL)METHYL] 1H IMIDAZOLE; 4 [N' (2 METHYLPHENYL)UREIDO]PHENYLACETYL DERIVATIVE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA4 BETA1 ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFUNGAL AGENT; ANTIMITOTIC AGENT; ANTIVIRUS AGENT; BENZAMIDINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CELECOXIB; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIGOXIN; DIHYDROFOLATE REDUCTASE INHIBITOR; IMIDAZOLE DERIVATIVE; LM 1685; MONOAMINE OXIDASE INHIBITOR; PIPERAZINE DERIVATIVE; PROTEIN INHIBITOR; PROTEIN N MYRISTOYLTRANSFERASE INHIBITOR; RECEPTOR BLOCKING AGENT; S 6716; SEROTONIN 1A ANTAGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROTENSIN II RECEPTOR ANTAGONIST; VERAPAMIL; VINBLASTINE;

ALGORITHM; ALZHEIMER DISEASE; CLINICAL TRIAL; COMPUTER MODEL; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG INFORMATION; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SCREENING; HUMAN; LIBRARY; NONHUMAN; PHARMACOPHORE; PUBLICATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; VALIDATION PROCESS;

COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG DESIGN; TECHNOLOGY, PHARMACEUTICAL;

EID: 0038458856     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Xu J, Hagler A: Chemainformatics and drug discovery. Molecules (2002) 7:566-600. This review covers the many applications of chemoinformatics, and their impact on modem drug discovery processes. Future directions are suggested.
2. Manly CJ, Louise-May S, Hammer JD: The impact of informatics and computational chemistry on synthesis and screening. Drug Disc Today (2001) 6:1101-1110. This review describes some of the successful strategies and applications of state-of-the-art algorithms to enhance drug discovery, as well as key points in the drug discovery process where computational methods can have, and have had, a great impact.
3. Moffet DA, Hecht MH: De novo proteins from combinatorial libraries. Chem Rev (2001) 101:3191-3203.
4. Langer T, Hoffmann RD: Virtual screening: An effective tool for lead structure discovery? Curr Pharm Design (2001) 7:509-527.
5. Walters WP, Stahl MT, Murcko MA: Virtual screening - An overview. Drug Disc Today (1998) 3:160-178. This review presents the state of VS in 1998, and discusses approaches that allow in silico evaluation of a large number of compounds.
6. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliver Rev (1997) 23:3-25. This classic work by Lipinski and colleagues offers the rule-of-five criteria, based on the analysis of drug permeability and solubility using calculated physicochemical properties.
7. Huuskonen J, Rantanen J, Livingstone D: Prediction of aqueous solubility for a diverse set of organic compounds based on atom-type electrotopological state indices. Eur J Med Chem (2000) 35:1081-1088.
8. Zuegge J, Schneider G, Coassolo P, Lave T: Prediction of hepatic metabolic clearance-comparison and assessment of prediction models. Clin Pharmacokin (2001) 40:553-563.
9. Abagyan R, Totrov M: High-throughput docking for lead generation. Curr Opin Chem Biol (2001) 5:375-382.
10. Diller DJ, Merz Jr KM: High throughput docking for library design and library prioritization. Proteins (2001) 43:113-124.
11. Schneider G, Böhm HJ: Virtual screening and fast automated docking methods. Drug Disc Today (2002) 7:64-70. This review provides a brief introduction to the basic principles of VS, and outlines computational tools currently used. Additionally, several successful examples of VS, highlighting the usefulness of this approach, are provided.
12. Stahl M, Rarey M: Detailed analysis of scoring functions for virtual screening. J Med Chem (2001) 44:1035-1042.
13. Charifson PS, Corkery JJ, Murcko MA, Walters WP: Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J Med Chem (1999) 42:5100-5109.
14. Wang R, Wang S: How does consensus scoring work for virtual library screening? An idealized computer experiment. J Chem Inf Comput Sci (2001) 41:1422-1426.
15. Jørgensen AM, Pedersen JT: Structural diversity of small molecule libraries. J Chem Inf Comput Sci (2001) 41:338-345.
16. Agrafiotis DK: A constant time algorithm for estimating the diversity of large chemical libraries. J Chem Inf Comput Sci (2001) 41:159-167.
17. Grahan ET, Jacober SP, Cardozo MG: A novel frequency distribution selection method for efficient plate layout of a diverse combinatorial library. J Chem Inf Comput Sci (2001) 41:1508-1516.
18. Reynolds CH, Tropsha A, Pfahler LB, Druker R, Chakravorty S, Ethiraj G, Zheng G: Diversity and coverage of structural sublibraries selected using the SAGE and SCA algorithms. J Chem Inf Comput Sci (2001) 41:1470-1477.
19. Wolber G, Langer T: Comb'Gen: A novel software package for the rapid generation of virtual combinatorial libraries. In: Rational Approaches to Drug Design. H61tje HD, Sippl W (Eds), Prous Science, Barcelona, Spain (2001):390-399.
20. Sadowski J, Kubinyi H: A scoring scheme for discriminating between drugs and non-drugs. J Med Chem (1998) 41:3325-3329.
21. Feher M, Schmid JM: Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci (2003) 43:218-227.
22. Lee ML, Schneider G: Scaffold architecture and pharmacaphoric properties of natural products and trade drugs: Application in the design of natural product-based combinatorial libraries. J Comb Chem (2001) 3:284-289.
23. Oprea TI, Gottfries J: Chemography: The art of navigating in chemical space. J Comb Chem (2001) 3:157-166.
24. Miller JL, Bradley EK, Teig SL: Luddlte: An information-theoretic library design tool. J Chem Inf Comput Sci (2003) 43:47-54.
25. Gillet VJ, Khatib W, Willett P, Fleming PJ, Green DVS: Combinatorial library design using a multiobjective genetic algorithm. J Chem Inf Comput Sci (2002) 42:375-385.
26. Roche O, Schneider P, Zuegge J, Guba W, Kansy M, Alanine A, Bleicher K, Danel F, Gutknecht EM, Rogers-Evans M, Neidhart W et al: Development of a virtual screening method for identification of 'frequent hitters' in compound libraries. J Med Chem (2002) 45:137-142. An interesting study, aimed at early in silico identification of possible promiscuous inhibitors to help reduce the number of false positives in VS.
27. McGovern SL, Caselli E, Grigorieff N, Shoichet BK: A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem (2002) 45:1712-1722. This important contribution reduces the number of false positive hits originating from HTS and VS. A plausible mechanism for the apparent promiscuity of a wide range of inhibitors identified in both HTS and VS is also presented.
28. Ajay A, Walters WP, Murcko MA: Can we learn to distinguish between 'drug-like' and 'non-drug-like' molecules? J Med Chem (1998) 41:3314-3324.
29. Xu J, Stevenson J: Drug-like index: A new approach to measure drug-like compounds and their diversity. J Chem Inf Comput Sci (2000) 40:1177-1187.
30. Oprea TI, Davis AM, Teague SJ, Leeson PD: Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comput Sci (2001) 41:1308-1315.
31. Proudfoot JR: Drugs, leads, and drug-likeness: An analysis of some recently launched drugs. Bioorg Med Chem Lett (2002) 12:1647-1650.
32. Grüneberg S, Stubbs MT, Klebe G: Successful virtual screening for novel inhibitors of human carbonic anhydrase: Strategy and experimental confirmation. J Med Chem (2002) 45:3588-3602.
33. Rarey M, Kramer B, Lengauer T, Klebe G: A fast flexible docking method using an incremental construction algorithm. J Mol Biol (1996) 261:470-489. An interesting theoretical study yielding compounds that exhibit affinity in the low nanomolar range. In two cases, the binding geometry prediction is validated by X-ray crystallography.
34. Liebeschuetz JW, Jones SD, Morgan PJ, Murray CW, Rimmer AD, Roscoe JME, Waszkowycz B, Welsh PM, Wylie WA, Young SC, Martin H et al: PRO_SELECT: Combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective Factor Xa inhibitors. J Med Chem (2002) 45:1221-1232.
35. Catalyst Environment. Accelrys Inc, San Diegó, CA, USA. http://www.accelrys.com/catalyst
36. Kurogi Y, Güner OF: Pharmacophore modeling and three-dimensional database searching for drug design using Catalyst. Curr Med Chem (2001) 8:1035-1055. This important review delivers insights into Catalyst's theory of pharmacophore generation processes, and lists a number of interesting applications.
37. 2-adrenoceptors. J Med Chem (2001) 44:2118-2132.
38. 1-Adrenoceptor antagonists. 4. Pharmacophore-based design, synthesis, and biological evaluation of new imidazo-, benzimidazo-, and indoloarylpiperazine derivatives. J Med Chem (2002) 45:3603-3611.
39. Singh J, van Vlijmen H, Liao Y, Lee W, Comebise M, Harris M, Shu I, Gill A, Cuervo JH, Abraham WM, Adams SP: Identification of potent and novel α4β1antagonists using in silico screening. J Med Chem (2002) 45:2988-2993. An outstanding work on pharmacophore modeling and in silico screening. Results are validated by in vitro and in vivo studies.
40. Tafi A, Costi R, Botta M, Di Santo R, Corelli F, Massa S, Ciacci A, Manetti F, Artico M: Antifungal agents. 10. New derivates of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-Candida activity, and quantitative structure-analysis relationship studies. J Med Chem (2002) 45:2720-2732.
41. Sterling J, Herzig Y, Goren T, Finkelstein N, Lerner D, Goldenberg W, Miskolczi I, Molnar S, Rantal F, Tamas T, Toth G et al: Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenylamine as potential treatment for Alzheimer's disease. J Med Chem (2002) 45:5260-5279.
42. 1A receptors. J Med Chem (2002) 45:4128-4139.
43. Flohr S, Kurz M, Kostenis E, Brkovich A, Fourier A, Klabunde T: Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear resonance studies on urotensin II. J Med Chem (2002) 45:1799-1805. A demonstration of the power of pharmacophore modeling, including NMR-based structural information and VS.
44. Saladino R, Crestini C, Palamara AT, Danti MC, Manetti F, Corelli F, Garaci E, Botta M: Synthesis, biological evaluation, and pharmacophore generation of uracil, 4(3H)-pyrimidone, and uridine derivates as potent and selective inhibitors of parainfluenza 1 (Sendal) virus. J Med Chem (2001) 44:4554-4562.
45. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan L, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol (2002) 61:974-981.
46. Krovat EM, Langer T: Non-peptide angiotensin II receptor antagonists: Chemical feature based pharmacophore identification. J Med Chem (2003) 46:716-726.
47. El Yazal J, Rao SN, Mehl A, Slikker WJ: Prediction of organophosphorus acetyicholinesterase inhibition using three-dimensional quantitative structure-activity relationship (3D-QSAR) methods. Toxicol Sci (2001) 63:223-232.
48. 4 receptor. J Chem Inf Comput Sci (2002) 42:962-967.
49. Kurogi Y, Miyata K, Okamura T, Hashimoto K, Tsutsumi K, Nasu M, Moriyasu M: Discovery of novel mesangial cell proliferation inhibitors using a three-dimensional database searching method. J Med Chem (2001) 44:2304-2307.
50. Karki RG, Kullarni VM: A feature based pharmacophore for Candida albicans MyristoylCoA: Protein N-myristoyitransferase inhibitors. Eur J Med Chem (2001) 36:147-163.
51. Debnath AK: Pharmacophore mapping of a series of 2,4-diamino-5-deazapterldine inhibitors of Mycobacterium avium complex dihydrofolate reductase. J Med Chem (2002) 45:41-53. An interesting article, in which a quantitative pharmacophore model is generated and validated.
52. Koide A, Hasegawa T, Takahaschi A, Endo A, Mochizuki N, Nakagawa M, Nishida A: Development of new EDG3 antagonists using a 3D database search and their structure-activity relationship. J Med Chem (2002) 45:4629-4638.
53. Palomer A, Cabre F, Pascual J, Campos J, Trujillo MA, Entrena A, Gallo MA, Garcia L, Mauleon D, Espinosa A: Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models. J Med Chem (2002) 45:1402-1411.
54. Szabo CM, Matsumura Y, Fukura S, Martin MB, Sanders JM, Sengupta S, Cieslak JA, Loftus TC, Lea CR, Lee HJ, Koohang A et al: Inhibition of geranylgeranyl diphosphate synthase by biphosphonates and diphosphates, A potential route to new bone antiresporption and antiparasitic agents. J Med Chem (2002) 45:2185-2196.
55. Bhattacharjee AK, Kyle DE, Vennerstrom JL, Milhous WK: A 3D QSAR pharmacophore model and quantum chemical structure-activity analysis of chloroquine (CQ)-resistance reversal. J Chem Inf Comput Sci (2002) 42:1212-1220.
56. 2 receptor antagonists. J Med Chem (2002) 45:2160-2172.
57. Bhattacharjee AK, Skanchy DJ, Jennings B, Hudson TH, Brendle JJ, Werbovetz KA: Analysis of stereoelectronic properties, mechanism of action and pharmacophore of synthetic indoio[2,1-b]quinazoline-6,12-dione derivatives in reaction to antileishmanial activity using quantum chemical, cyclic voltametry and 3-D-QSAR CATALYST procedures. Bioorg Med Chem (2002) 10:1979-1989.
58. 14C]acetate Incorporation in Plodia Interpunctella. Bioorg Med Chem (2003) 11:95-103.
59. Hirashima A, Morimoto M, Muwano E, Taniguchi E, Eto M: Three-dimensional common-feature hypothesis for octapamine agonist arylethanolamines. J Mol Graph (2002) 21:81-87.
60. Chen GS, Chang CS, Kan WM, Chang CL, Wang KC, Chern JW: Novel lead generation through hypothethical pharmacephore three-dimensional database searching: Discovery of isoflavanoids as nonsteroidal inhibitors of rat 5α-reductase. J Med Chem (2001) 44:3759-3763.
61. Hecker EA, Duraiswami C, Tariq AA, Diller DJ: Use of catalyst pharmacophore models for screening of large combinatorial libraries. J Chem Inf Comput Sci (2002) 42:1204-1211.
62. Viswanadhan VN, Balan C, Hulme C, Cheetham GC, Sun Y: Knowledge-based approaches in the design and selection of compound libraries for drug discovery. Curr Opin Drug Discovery Dev (2002) 5:400-406. This important review delivers insights into state-of-the-art methods currently used for drug property range prediction.